ReddyPort™ Elbow Non-Invasive Ventilation Product Receives CE Mark Approval

ReddyPort, a medical technology company focused on solutions that enable better care experiences for patients on non-invasive ventilation (NIV), announced today that it has received Conformité Européene (CE) Mark approval for ReddyPort™ Elbow.

The CE marking confirms that ReddyPort, a suite of solutions that promotes NIV success, and allows clinicians to perform procedures through the ventilation mask without interrupting therapeutic pressure meets the requirements of the European Medical Devices Directive (MDD). This now allows ReddyPort to commercialize ReddyPort™ Elbow across the European Union and other CE Mark geographies.

“CE Mark is an important milestone and validation of our vision to make ReddyPort the standard of care for patients on NIV,” said Scott Bostick, chief executive officer of ReddyPort. CE Mark approval means we can help patients in Europe who struggle tolerating NIV therapy due to known issues while wearing the mask; dry-mouth, phlegm build-up, and difficulty communicating. ReddyPort™ Elbow and oral care products help improve tolerance, patient compliance, and comfort, leading to more successful NIV. Supporting a successful NIV is especially important now as clinicians need it most during the COVID-19 pandemic.”

NIV is the first line of therapy in respiratory insufficiency or failure, commonly seen with COPD, CHF, asthma, pneumonia or ARDS1. NIV intolerance can lead to failure and escalation of care with mechanical ventilation. ReddyPort products promote NIV success, by empowering clinicians and patients with simplified oral access without interrupting patient therapy.

ReddyPort features a proprietary elbow with self-sealing valve that provides access to the patient’s mouth. ReddyPort™ Elbow, in combination with ReddyPort™ NIV Maintenance Kit, allows the ability to clean and moisturize the patient’s mouth without mask removal. Oral hygiene is proven to help reduce risk of infection and improve patient satisfaction.


Reference:


1 Rochwerg B, Brochard L, Elliott MW, Hess D, et al. Official ERS/ATS Clinical Practice Guidelines: Noninvasive Ventilation for Acute Respiratory Failure. Eur Respir J. 2017: 31;50(2):1602426.

SourceReddyPort

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version